CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Latest Progress, Future Possibilities, and Implications for Patient Care

Deepen your understanding on guideline concordant treatment for early or metastatic HR-positive/HER2-negative breast cancer, with a focus on the appropriate use of CDK4/6 inhibitors and toxicity management related to these therapies, through on-demand webcasts with accompanying slides and an expert-written ClinicalThought commentary.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner